Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval
Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic…
Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza vaccine 2 overview
Vaccine is under development for the prevention of infections caused by pandemic influenza virus. The vaccine works by inducing the body's immune response.
Shanghai Institute of Biological Products overview
Shanghai Institute of Biological Products (SIBP) engaged in production and distribution of bacterial and virus vaccines, toxoids, and analogous products. It serves various markets including medical clinics and hospitals, pharmaceuticals, health information systems, dental and orthodontic practitioners. The company is headquartered in Shanghai, China.
For a complete picture of Influenza vaccine 2’s drug-specific PTSR and LoA scores, buy the report here.
What's Your Reaction?
